Clinical Trial Update: Creatine Safety and Tolerability in Premanifest HD: PRECREST [Phase 2]

View source ↗

Summary

This Phase 2 study (PRECREST) evaluated the safety and tolerability of creatine in individuals with premanifest Huntington disease and has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Huntington Disease

Drugs mentioned

• Creatine (creatine)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Huntington Disease | Phase 2 | Status: COMPLETED